887752-12-7Relevant academic research and scientific papers
Controlled formation of mono- and dihydroxy-resolvins from EPA and DHA using soybean 15-lipoxygenase
Dobson, Eleanor P.,Barrow, Colin J.,Kralovec, Jaroslav A.,Adcock, Jacqui L.
, p. 1439 - 1447 (2013)
Resolvins and protectins are important anti-infl ammatory and pro-resolution compounds derived from the enzymatic oxidation of omega-3 fatty acids all -cis -5,8,11,14,17- eicosapentaenoic acid (EPA) and all -cis -4,7,10,13,16,19-docosahexaenoic acid (DHA). We have developed a simple, controlled method to synthesize an array of resolvin and protectin analogs from fatty acid starting materials using soybean 15-lipoxygenase. The conditions were optimized for the production of both mono- and dihydroxy derivatives, with enzyme concentration and pH found to have a signifi cant effect on the reaction products. The methods were applied to fi ve biologically important omega-3 and omega-6 fatty acid substrates. Mono- and dihydroxy compounds were successfully synthesized from all substrates and the products were characterized by normal phase (NP) HPLC , GC-MS, TOF-MS, UV-visible (UV-vis) spectroscopy, and NMR spectroscopy. The methods could be further applied to any polyunsaturated fatty acids containing the cis -1,4,7,10-undecatetraene moiety to produce a range of novel compounds with potential biological activity. Copyright
OXYLIPINS FROM LONG CHAIN POLYUNSATURATED FATTY ACIDS AND METHODS OF MAKING AND USING THE SAME
-
Page/Page column 57-58, (2008/06/13)
Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.
